Literature DB >> 8201342

Surface EMG and muscle fibre conduction during attacks of hypokalaemic periodic paralysis.

T P Links1, J H van der Hoeven, M J Zwarts.   

Abstract

Surface EMG, muscle fibre conduction velocity (MFCV), muscle force, and biochemical variables were investigated in a 13-year-old boy with familial hypokalaemic periodic paralysis during and after three attacks of paralysis. After normalisation of the serum potassium values, strength rapidly returned to interictal values, but the integrated EMG and to a lesser extent the MFCV recovered more slowly. These findings suggest that a complete electrophysiological recovery is not necessary for a restoration of muscle force and that the pathogenetic defect is localised in the muscle membrane.

Entities:  

Mesh:

Year:  1994        PMID: 8201342      PMCID: PMC1072933          DOI: 10.1136/jnnp.57.5.632

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  CLINICAL AND ELECTROMYOGRAPHIC STUDIES IN A PATIENT WITH PRIMARY HYPOKALEMIC PERIODIC PARALYSIS.

Authors:  A G ENGEL; E H LAMBERT; J W ROSEVEAR; W N TAUXE
Journal:  Am J Med       Date:  1965-04       Impact factor: 4.965

2.  The muscle fiber conduction velocity and power spectra in familial hypokalemic periodic paralysis.

Authors:  M J Zwarts; T W van Weerden; T P Links; H T Haenen; H J Oosterhuis
Journal:  Muscle Nerve       Date:  1988-02       Impact factor: 3.217

3.  Effect of electrode parameters on the bandwidth of the surface e.m.g. power-density spectrum.

Authors:  P Zipp
Journal:  Med Biol Eng Comput       Date:  1978-09       Impact factor: 2.602

4.  Familial hypokalemic periodic paralysis.

Authors:  J F Campa; D B Sanders
Journal:  Arch Neurol       Date:  1974-08

5.  Hypokalemic periodic paralysis studies in vitro.

Authors:  W W Hofmann; R A Smith
Journal:  Brain       Date:  1970       Impact factor: 13.501

6.  Long-lasting supernormal conduction velocity after sustained maximal isometric contraction in human muscle.

Authors:  J H van der Hoeven; T W van Weerden; M J Zwarts
Journal:  Muscle Nerve       Date:  1993-03       Impact factor: 3.217

7.  Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects.

Authors:  T P Links; M J Zwarts; J T Wilmink; W M Molenaar; H J Oosterhuis
Journal:  Brain       Date:  1990-12       Impact factor: 13.501

8.  Conduction velocities in single fibers of diseased human muscle.

Authors:  R Gruener; L Z Stern; R R Weisz
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

9.  Myoglobin, creatine kinase and creatine kinase subunit-beta in serum from patients and relatives with hypokaliaemic familial periodic paralysis.

Authors:  P Wiggers; K Nørregaard-Hansen
Journal:  Acta Neurol Scand       Date:  1985-01       Impact factor: 3.209

10.  Hypokalemic periodic paralysis. A single fiber electromyographic study.

Authors:  D De Grandis; A Fiaschi; G Tomelleri; D Orrico
Journal:  J Neurol Sci       Date:  1978-06       Impact factor: 3.181

View more
  4 in total

Review 1.  Periodic paralysis: understanding channelopathies.

Authors:  Frank Lehmann-Horn; Karin Jurkat-Rott; Reinhardt Rüdel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

2.  Voltage-dependent Ca2+ release is impaired in hypokalemic periodic paralysis caused by CaV1.1-R528H but not by NaV1.4-R669H.

Authors:  Marino DiFranco; Stephen C Cannon
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

Review 3.  Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder.

Authors:  Bertrand Fontaine; Emmanuel Fournier; Damien Sternberg; Savine Vicart; Nacira Tabti
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 4.  Clinical evaluation of membrane excitability in muscle channel disorders: potential applications in clinical trials.

Authors:  James C Cleland; Eric L Logigian
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.